Trials / Recruiting
RecruitingNCT04799002
Topotecan and Melphalan for Retinoblastoma
Choice of Topotecan or Melphalan in Retinoblastoma Patients
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Detailed description
To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Topotecan | Topotecan intraocular injection for chemotherapy in retinoblastoma |
| DRUG | Melphalan | Melphalan intraocular injection for chemotherapy in retinoblastoma |
Timeline
- Start date
- 2021-03-11
- Primary completion
- 2024-12-30
- Completion
- 2027-12-30
- First posted
- 2021-03-16
- Last updated
- 2021-03-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04799002. Inclusion in this directory is not an endorsement.